WCN26-6471 BEVACIZUMAB-ASSOCIATED KIDNEY TOXICITY IN ONCOLOGY PATIENTS: AN ONCONEPHROLOGY PERSPECTIVE FROM A MULTI-ETHNIC COHORT IN SOUTHEAST ASIA

Read full text Summarise with VIRAT
Authors: Jia Yee Wong, Jia Yee Wong, Han Hwa Lee, Y. C. Hooi, Megan Chong Jing Yi, Uma Devi Markandan, Carven Lit Kar Wen, Marniza Bte Saad, Soo Kun Lim, Chew Ming Wong
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), improves outcomes in advanced malignancies but can precipitate kidney toxicity. Real-world data from Southeast Asia are limited. This study evaluated the prevalence, spectrum, predictors, nephrology referral patterns, and survival outcomes of bevacizumab-associated kidney toxicity in a multi-ethnic Malaysian cohort.

Fields of Study & Subjects

Acute Kidney Injury Research Chemotherapy-induced organ toxicity mitigation Renal Diseases and Glomerulopathies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105968–105968
Publication date
25 March 2026
Language
EN